Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 240

1.

The effects of soy supplementation on gene expression in breast cancer: a randomized placebo-controlled study.

Shike M, Doane AS, Russo L, Cabal R, Reis-Filho JS, Gerald W, Cody H, Khanin R, Bromberg J, Norton L.

J Natl Cancer Inst. 2014 Sep 4;106(9). pii: dju189. doi: 10.1093/jnci/dju189. Print 2014 Sep.

2.

Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.

Wang G, Lunardi A, Zhang J, Chen Z, Ala U, Webster KA, Tay Y, Gonzalez-Billalabeitia E, Egia A, Shaffer DR, Carver B, Liu XS, Taulli R, Kuo WP, Nardella C, Signoretti S, Cordon-Cardo C, Gerald WL, Pandolfi PP.

Nat Genet. 2013 Jul;45(7):739-746. doi: 10.1038/ng.2654. Epub 2013 Jun 2.

3.

A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.

Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack EC, Lis R, Patnaik A, Cantley LC, Bubley G, Cordon-Cardo C, Gerald WL, Montironi R, Signoretti S, Loda M, Nardella C, Pandolfi PP.

Nat Genet. 2013 Jul;45(7):747-55. doi: 10.1038/ng.2650. Epub 2013 Jun 2.

4.

Expression of androgen receptor and its phosphorylated forms in breast cancer progression.

Ren Q, Zhang L, Ruoff R, Ha S, Wang J, Jain S, Reuter V, Gerald W, Giri DD, Melamed J, Garabedian MJ, Lee P, Logan SK.

Cancer. 2013 Jul 15;119(14):2532-40. doi: 10.1002/cncr.28092. Epub 2013 Apr 19.

5.

Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer.

Ha S, Iqbal NJ, Mita P, Ruoff R, Gerald WL, Lepor H, Taneja SS, Lee P, Melamed J, Garabedian MJ, Logan SK.

Oncogene. 2013 Aug 22;32(34):3992-4000. doi: 10.1038/onc.2012.412. Epub 2012 Sep 17.

6.

Stat3 mediates expression of autotaxin in breast cancer.

Azare J, Doane A, Leslie K, Chang Q, Berishaj M, Nnoli J, Mark K, Al-Ahmadie H, Gerald W, Hassimi M, Viale A, Stracke M, Lyden D, Bromberg J.

PLoS One. 2011;6(11):e27851. doi: 10.1371/journal.pone.0027851. Epub 2011 Nov 28.

7.

MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.

Huang R, Cheung NK, Vider J, Cheung IY, Gerald WL, Tickoo SK, Holland EC, Blasberg RG.

FASEB J. 2011 Dec;25(12):4138-49. doi: 10.1096/fj.11-185033. Epub 2011 Aug 19.

8.

Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression.

Chen M, Pratt CP, Zeeman ME, Schultz N, Taylor BS, O'Neill A, Castillo-Martin M, Nowak DG, Naguib A, Grace DM, Murn J, Navin N, Atwal GS, Sander C, Gerald WL, Cordon-Cardo C, Newton AC, Carver BS, Trotman LC.

Cancer Cell. 2011 Aug 16;20(2):173-86. doi: 10.1016/j.ccr.2011.07.013.

9.

MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors.

Clegg NJ, Couto SS, Wongvipat J, Hieronymus H, Carver BS, Taylor BS, Ellwood-Yen K, Gerald WL, Sander C, Sawyers CL.

PLoS One. 2011 Mar 4;6(3):e17449. doi: 10.1371/journal.pone.0017449.

10.

Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases.

Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, Park BJ, Rusch VW, Travis WD.

Mod Pathol. 2011 May;24(5):653-64. doi: 10.1038/modpathol.2010.232. Epub 2011 Jan 21.

11.

Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signalling.

Rajasekhar VK, Studer L, Gerald W, Socci ND, Scher HI.

Nat Commun. 2011 Jan 18;2:162.

12.

Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development.

Bianco-Miotto T, Chiam K, Buchanan G, Jindal S, Day TK, Thomas M, Pickering MA, O'Loughlin MA, Ryan NK, Raymond WA, Horvath LG, Kench JG, Stricker PD, Marshall VR, Sutherland RL, Henshall SM, Gerald WL, Scher HI, Risbridger GP, Clements JA, Butler LM, Tilley WD, Horsfall DJ, Ricciardelli C; Australian Prostate Cancer BioResource.

Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2611-22. doi: 10.1158/1055-9965.EPI-10-0555. Epub 2010 Sep 14.

13.

Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.

Dahlman A, Edsjö A, Halldén C, Persson JL, Fine SW, Lilja H, Gerald W, Bjartell A.

Prostate Cancer Prostatic Dis. 2010 Dec;13(4):369-75. doi: 10.1038/pcan.2010.25. Epub 2010 Aug 3.

PMID:
20680031
14.

Copy number and gene expression differences between African American and Caucasian American prostate cancer.

Rose AE, Satagopan JM, Oddoux C, Zhou Q, Xu R, Olshen AB, Yu JZ, Dash A, Jean-Gilles J, Reuter V, Gerald WL, Lee P, Osman I.

J Transl Med. 2010 Jul 22;8:70. doi: 10.1186/1479-5876-8-70.

15.

Integrative genomic profiling of human prostate cancer.

Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL.

Cancer Cell. 2010 Jul 13;18(1):11-22. doi: 10.1016/j.ccr.2010.05.026. Epub 2010 Jun 24.

16.

TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features.

Fine SW, Gopalan A, Leversha MA, Al-Ahmadie HA, Tickoo SK, Zhou Q, Satagopan JM, Scardino PT, Gerald WL, Reuter VE.

Mod Pathol. 2010 Oct;23(10):1325-33. doi: 10.1038/modpathol.2010.120. Epub 2010 Jun 18.

17.

18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis.

Osborne JR, Port E, Gonen M, Doane A, Yeung H, Gerald W, Cook JB, Larson S.

J Nucl Med. 2010 Apr;51(4):543-50. doi: 10.2967/jnumed.108.060459. Epub 2010 Mar 17.

18.

Biobanking of human pancreas cancer tissue: impact of ex-vivo procurement times on RNA quality.

Rudloff U, Bhanot U, Gerald W, Klimstra DS, Jarnagin WR, Brennan MF, Allen PJ.

Ann Surg Oncol. 2010 Aug;17(8):2229-36. doi: 10.1245/s10434-010-0959-6. Epub 2010 Feb 17.

19.

Identification of DOK genes as lung tumor suppressors.

Berger AH, Niki M, Morotti A, Taylor BS, Socci ND, Viale A, Brennan C, Szoke J, Motoi N, Rothman PB, Teruya-Feldstein J, Gerald WL, Ladanyi M, Pandolfi PP.

Nat Genet. 2010 Mar;42(3):216-23. doi: 10.1038/ng.527. Epub 2010 Feb 7.

20.

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.

Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM, Foster CS, Fletcher A, Gerald WL, Møller H, Reuter VE, Scardino PT, Cuzick J, de Bono JS, Cooper CS; Transatlantic Prostate Group.

Br J Cancer. 2010 Feb 16;102(4):678-84. doi: 10.1038/sj.bjc.6605554. Epub 2010 Jan 26.

21.

Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA.

Wang L, Zou X, Berger AD, Twiss C, Peng Y, Li Y, Chiu J, Guo H, Satagopan J, Wilton A, Gerald W, Basch R, Wang Z, Osman I, Lee P.

Am J Transl Res. 2009;1(1):62-71. Epub 2009 Jan 1.

22.

Enteric neural crest differentiation in ganglioneuromas implicates Hedgehog signaling in peripheral neuroblastic tumor pathogenesis.

Gershon TR, Shiraz A, Qin LX, Gerald WL, Kenney AM, Cheung NK.

PLoS One. 2009 Oct 16;4(10):e7491. doi: 10.1371/journal.pone.0007491. Erratum in: PLoS One. 2014 Jul 25;9(7):e103881. Shirazi, Arash [corrected to Shiraz, Ashton].

23.

Differential p53-independent outcomes of p19(Arf) loss in oncogenesis.

Chen Z, Carracedo A, Lin HK, Koutcher JA, Behrendt N, Egia A, Alimonti A, Carver BS, Gerald W, Teruya-Feldstein J, Loda M, Pandolfi PP.

Sci Signal. 2009 Aug 18;2(84):ra44. doi: 10.1126/scisignal.2000053.

24.

PIK3CA mutation associates with improved outcome in breast cancer.

Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W, Moynahan ME.

Clin Cancer Res. 2009 Aug 15;15(16):5049-59. doi: 10.1158/1078-0432.CCR-09-0632. Epub 2009 Aug 11.

25.

NF-kappaB regulates androgen receptor expression and prostate cancer growth.

Zhang L, Altuwaijri S, Deng F, Chen L, Lal P, Bhanot UK, Korets R, Wenske S, Lilja HG, Chang C, Scher HI, Gerald WL.

Am J Pathol. 2009 Aug;175(2):489-99. doi: 10.2353/ajpath.2009.080727. Epub 2009 Jul 23.

26.

WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis.

Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, Gerald WL, Massagué J.

Cell. 2009 Jul 10;138(1):51-62. doi: 10.1016/j.cell.2009.04.030. Epub 2009 Jul 2.

27.

Latent bone metastasis in breast cancer tied to Src-dependent survival signals.

Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA, Massagué J.

Cancer Cell. 2009 Jul 7;16(1):67-78. doi: 10.1016/j.ccr.2009.05.017.

28.

An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors.

Chitale D, Gong Y, Taylor BS, Broderick S, Brennan C, Somwar R, Golas B, Wang L, Motoi N, Szoke J, Reinersman JM, Major J, Sander C, Seshan VE, Zakowski MF, Rusch V, Pao W, Gerald W, Ladanyi M.

Oncogene. 2009 Aug 6;28(31):2773-83. doi: 10.1038/onc.2009.135. Epub 2009 Jun 15.

29.

The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.

Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, Mischel PS, Sander C, Taylor B, Schultz N, Major J, Heguy A, Fang F, Mellinghoff IK, Chan TA.

Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9435-40. doi: 10.1073/pnas.0900571106. Epub 2009 May 28.

30.

Genes that mediate breast cancer metastasis to the brain.

Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, Massagué J.

Nature. 2009 Jun 18;459(7249):1005-9. doi: 10.1038/nature08021. Epub 2009 May 6.

31.

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP.

Nat Genet. 2009 May;41(5):619-24. doi: 10.1038/ng.370. Epub 2009 Apr 26.

32.

Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.

King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, Gerald WL, Sawyers CL.

Nat Genet. 2009 May;41(5):524-6. doi: 10.1038/ng.371. Epub 2009 Apr 26.

33.

Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer.

Sheffer M, Bacolod MD, Zuk O, Giardina SF, Pincas H, Barany F, Paty PB, Gerald WL, Notterman DA, Domany E.

Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7131-6. doi: 10.1073/pnas.0902232106. Epub 2009 Apr 9.

34.

Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells.

Nwachukwu JC, Mita P, Ruoff R, Ha S, Wang Q, Huang SJ, Taneja SS, Brown M, Gerald WL, Garabedian MJ, Logan SK.

Cancer Res. 2009 Apr 1;69(7):3140-7. doi: 10.1158/0008-5472.CAN-08-3738. Epub 2009 Mar 24.

35.

Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study.

Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS, Reuter V, Eastham J, Moller H, Kattan MW, Gerald W, Cooper C, Scardino P, Cuzick J.

Br J Cancer. 2009 Mar 24;100(6):888-93. doi: 10.1038/sj.bjc.6604951.

36.

Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.

Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL, Mills GB, Hennessy BT.

Clin Cancer Res. 2009 Apr 1;15(7):2472-8. doi: 10.1158/1078-0432.CCR-08-1763. Epub 2009 Mar 10.

37.

ETS rearrangements and prostate cancer initiation.

Carver BS, Tran J, Chen Z, Carracedo-Perez A, Alimonti A, Nardella C, Gopalan A, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP.

Nature. 2009 Feb 12;457(7231):E1; discussion E2-3. doi: 10.1038/nature07738.

38.

Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma.

Lavarino C, Cheung NK, Garcia I, Domenech G, de Torres C, Alaminos M, Rios J, Gerald WL, Kushner B, LaQuaglia M, Mora J.

BMC Cancer. 2009 Feb 3;9:44. doi: 10.1186/1471-2407-9-44.

39.

TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.

Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW, Eastham JA, Scardino PT, Scher HI, Tickoo SK, Reuter VE, Gerald WL.

Cancer Res. 2009 Feb 15;69(4):1400-6. doi: 10.1158/0008-5472.CAN-08-2467. Epub 2009 Feb 3.

40.

MDM2 expression and regulation in prostate cancer racial disparity.

Wang G, Firoz EF, Rose A, Blochin E, Christos P, Pollens D, Mazumdar M, Gerald W, Oddoux C, Lee P, Osman I.

Int J Clin Exp Pathol. 2009;2(4):353-60. Epub 2008 Dec 4.

41.

Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling.

Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, Giancotti FG.

J Clin Invest. 2009 Feb;119(2):252-66. doi: 10.1172/JCI37160. Epub 2009 Jan 19.

42.

The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer.

Shen H, Powers N, Saini N, Comstock CE, Sharma A, Weaver K, Revelo MP, Gerald W, Williams E, Jessen WJ, Aronow BJ, Rosson G, Weissman B, Muchardt C, Yaniv M, Knudsen KE.

Cancer Res. 2008 Dec 15;68(24):10154-62. doi: 10.1158/0008-5472.CAN-08-1794.

43.

Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma.

Cheung IY, Feng Y, Gerald W, Cheung NK.

Clin Cancer Res. 2008 Nov 1;14(21):7020-7. doi: 10.1158/1078-0432.CCR-08-0541.

44.

Analytical validation of the GeXP analyzer and design of a workflow for cancer-biomarker discovery using multiplexed gene-expression profiling.

Rai AJ, Kamath RM, Gerald W, Fleisher M.

Anal Bioanal Chem. 2009 Mar;393(5):1505-11. doi: 10.1007/s00216-008-2436-7. Epub 2008 Oct 29.

PMID:
18958454
45.

Solitary relapse of desmoplastic small round cell tumor detected by positron emission tomography/computed tomography.

Kushner BH, Laquaglia MP, Gerald WL, Kramer K, Modak S, Cheung NK.

J Clin Oncol. 2008 Oct 20;26(30):4995-6. doi: 10.1200/JCO.2008.17.9457. Epub 2008 Sep 22. No abstract available.

46.

Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model.

Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C.

J Clin Invest. 2008 Sep;118(9):3051-64. doi: 10.1172/JCI34764.

47.

Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events.

Nardella C, Chen Z, Salmena L, Carracedo A, Alimonti A, Egia A, Carver B, Gerald W, Cordon-Cardo C, Pandolfi PP.

Genes Dev. 2008 Aug 15;22(16):2172-7. doi: 10.1101/gad.1699608.

48.

Differential expression of genes mapping to recurrently abnormal chromosomal regions characterize neuroblastic tumours with distinct ploidy status.

Lavarino C, Garcia I, Mackintosh C, Cheung NK, Domenech G, Ríos J, Perez N, Rodríguez E, de Torres C, Gerald WL, Tuset E, Acosta S, Beleta H, de Alava E, Mora J.

BMC Med Genomics. 2008 Aug 13;1:36. doi: 10.1186/1755-8794-1-36.

49.

Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study.

Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma, Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, Chang AC, Zhu CQ, Strumpf D, Hanash S, Shepherd FA, Ding K, Seymour L, Naoki K, Pennell N, Weir B, Verhaak R, Ladd-Acosta C, Golub T, Gruidl M, Sharma A, Szoke J, Zakowski M, Rusch V, Kris M, Viale A, Motoi N, Travis W, Conley B, Seshan VE, Meyerson M, Kuick R, Dobbin KK, Lively T, Jacobson JW, Beer DG.

Nat Med. 2008 Aug;14(8):822-7. doi: 10.1038/nm.1790. Epub 2008 Jul 20.

50.

KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis.

Narla G, DiFeo A, Fernandez Y, Dhanasekaran S, Huang F, Sangodkar J, Hod E, Leake D, Friedman SL, Hall SJ, Chinnaiyan AM, Gerald WL, Rubin MA, Martignetti JA.

J Clin Invest. 2008 Aug;118(8):2711-21. doi: 10.1172/JCI34780.

Supplemental Content

Loading ...
Support Center